We observed these cell cycle alterations and the induction of the subG1 fractions similarly in MOLM-13 cells (express FLT3-ITD and wild-type FLT3, from a 20-year-old man with AML cells after initial myelodysplastic syndrome) that we treated with 2 nM AC220 ± 2 nM FK228 (Fig. 1D). This evidence concerns the gene FLT3 and myelodysplastic syndrome.